Trevena Inc Stock Price, News & Analysis

Trevena, Inc. (Nasdaq: TRVN) announced a commercial launch of OLINVYK with an expanded medical team targeting key decision-makers. The company initiated a new cognitive function study comparing OLINVYK and IV morphine, with enrollment starting in Q1 2022. Ongoing studies include evaluations of OLINVYK's effects on respiratory and gastrointestinal functions. Despite a net loss of $13.9M in Q3 2021, Trevena reported $78.6M in cash, projected to support operations through 2022. A conference call is scheduled for November 15, 2021, to discuss results and updates.

Trevena, Inc. (Nasdaq: TRVN) has appointed Patricia Drake as the new Chief Commercial Officer, effective immediately. With over 30 years of experience, Drake aims to enhance the market presence of OLINVYK, Trevena's opioid analgesic approved by the FDA in August 2020. Under her guidance, the company plans to accelerate formulary wins and optimize its sales strategy. Bob Yoder also assumes the role of Chief Business Officer, working with Drake to bolster OLINVYK's launch and advance the company's clinical pipeline, particularly focusing on TRV027 for various indications.

Trevena, Inc. (Nasdaq: TRVN) reported it will release its third-quarter financial results for 2021 on November 15, at 8:00 a.m. ET. The announcement includes a conference call that will feature management and insights from Paul F. Rider, M.D. about the use of OLINVYK in colorectal surgery. The company continues to focus on CNS disorders and has one approved product, OLINVYK, along with several investigational drug candidates targeting various medical conditions.

Trevena, Inc. (TRVN) announced two presentations at the ANESTHESIOLOGY 2021 conference, focusing on safety data from the OLINVYK (oliceridine) injection program. The studies demonstrated that obese patients and those with moderate to severe renal impairment are not at an increased risk for opioid-related adverse events (ORAEs). The OLINVYK program aims to provide valuable information for post-operative care. OLINVYK is a FDA-approved analgesic for acute pain management, addressing a significant medical need.

Trevena, Inc. (Nasdaq: TRVN) announced promising results from its proof-of-concept study of TRV027 in hospitalized COVID-19 patients. The data showed a 92% probability of TRV027's beneficial impact on D-dimer levels, a key biomarker for critical illness. Patients treated with TRV027 experienced a 12-day lower average hospital stay compared to placebo. The study included 30 patients, with 70% of those treated showing reduced D-dimer levels. TRV027 is being evaluated in larger ongoing studies (ACTIV-4 and REMAP-CAP), with data expected in mid-2022.

Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on CNS disorders, will present at the Oppenheimer 2021 Fall Healthcare Life Sciences & MedTech Summit from September 20-23, 2021. Carrie Bourdow, President and CEO, will deliver the presentation on September 21 at 8:15 a.m. ET. A webcast link is available on the company’s website, with the replay accessible for 30 days post-event. Trevena's pipeline includes investigational drugs TRV250, TRV734, TRV045, and TRV027, aimed at various CNS conditions and COVID-19 complications.

Imvax announced the appointment of John M. Limongelli as the Chief Legal Officer effective September 16, 2021. Limongelli brings nearly 25 years of experience in the biopharma industry, having previously held significant roles at Neos Therapeutics and Trevena, Inc. (NASDAQ: TRVN). His expertise is expected to enhance Imvax's leadership as the company focuses on expanding its immunotherapy platform for solid tumors, with IGV-001 aimed at treating glioblastoma. CEO John Furey highlighted Limongelli's potential contributions to the company's growth.

On September 9, 2021, Trevena (Nasdaq: TRVN) announced that Carrie Bourdow, its President and CEO, will present at the H.C. Wainwright 23rd Annual Global Investment Conference from September 13-15, 2021. The presentation will occur on September 13 at 7:00 a.m. ET.

A webcast link will be available on the company’s Investors page, and a replay will be accessible for 30 days post-event. Trevena is focused on CNS disorders and has one approved product, OLINVYK®, along with a pipeline of investigational drug candidates.

Trevena, Inc. (Nasdaq: TRVN) announced the acceptance of two abstracts at ANESTHESIOLOGY® 2021, focusing on the safety data from the OLINVYK (oliceridine) injection program. The conference, held from October 8 to 12 in San Diego, will feature a top research abstract and highlights from two e-posters. OLINVYK is FDA-approved for managing acute pain in adults requiring intravenous opioid analgesics. The company continues to emphasize the medical community's interest in OLINVYK's profile.